Adaptive Biotechnologies Q3 revenue $94M (+102% YoY); MRD profitable, guidance raised

Adaptive Biotechnologies Corp

2025-Q3 EPS reported -$0.30 revenue$205,295,000

Revenue $94.0M (up 102% YoY) includes $33.7M from full amortization of Genentech payment.
MRD revenue $56.8M (+52% YoY); MRD achieved profitability and cash flow positivity with Adj. EBITDA $7.0M.
clonoSEQ test volume 27,111 (+38% YoY); NCCN guidelines updated for CLL MRD-guided treatment duration.
Net income $9.5M vs $32.1M loss in Q3 2024; Adj. EBITDA $28.0M vs $14.3M loss.
FY2025 MRD revenue guidance raised to $202-207M; total operating spend and cash burn guidance reduced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.